These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31725756)

  • 1. Importance of thorough tissue and cellular level characterization of targeted drugs in the evaluation of pharmacodynamic effects.
    Bauknight DK; Osinski V; Dasa SSK; Nguyen AT; Marshall MA; Hartman J; Harms M; O'Mahony G; Boucher J; Klibanov AL; McNamara CA; Kelly KA
    PLoS One; 2019; 14(11):e0224917. PubMed ID: 31725756
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Osinski V; Bauknight DK; Dasa SSK; Harms MJ; Kroon T; Marshall MA; Garmey JC; Nguyen AT; Hartman J; Upadhye A; Srikakulapu P; Zhou A; O'Mahony G; Klibanov AL; Kelly KA; Boucher J; McNamara CA
    Theranostics; 2020; 10(2):585-601. PubMed ID: 31903139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NPY
    Wittrisch S; Klöting N; Mörl K; Chakaroun R; Blüher M; Beck-Sickinger AG
    Mol Metab; 2020 Jan; 31():163-180. PubMed ID: 31918918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice.
    Cha DR; Zhang X; Zhang Y; Wu J; Su D; Han JY; Fang X; Yu B; Breyer MD; Guan Y
    Diabetes; 2007 Aug; 56(8):2036-45. PubMed ID: 17536062
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar.
    Hegarty BD; Furler SM; Oakes ND; Kraegen EW; Cooney GJ
    Endocrinology; 2004 Jul; 145(7):3158-64. PubMed ID: 15059948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrin Targeting and Toxicological Assessment of Peptide-Conjugated Liposome Delivery Systems to Activated Endothelial Cells.
    Kermanizadeh A; Villadsen K; Østrem RG; Jensen KJ; Møller P; Loft S
    Basic Clin Pharmacol Toxicol; 2017 Apr; 120(4):380-389. PubMed ID: 27767251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-based targeted delivery of a peptide modified nanocarrier to endothelial cells in adipose tissue.
    Hossen MN; Kajimoto K; Akita H; Hyodo M; Ishitsuka T; Harashima H
    J Control Release; 2010 Oct; 147(2):261-8. PubMed ID: 20647023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting curcusomes to inflammatory dendritic cells inhibits NF-κB and improves insulin resistance in obese mice.
    Yekollu SK; Thomas R; O'Sullivan B
    Diabetes; 2011 Nov; 60(11):2928-38. PubMed ID: 21885868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Saroglitazar reduces obesity and associated inflammatory consequences in murine adipose tissue.
    Kumar D; Goand UK; Gupta S; Shankar K; Varshney S; Rajan S; Srivastava A; Gupta A; Vishwakarma AL; Srivastava AK; Gaikwad AN
    Eur J Pharmacol; 2018 Mar; 822():32-42. PubMed ID: 29331565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proliferative and molecular effects of the dual PPARalpha/gamma agonist tesaglitazar in rat adipose tissues: relevance for induction of fibrosarcoma.
    Glinghammar B; Berg AL; Bjurström S; Stockling K; Blomgren B; Westerberg R; Skånberg I; Hellmold H; Andersson U
    Toxicol Pathol; 2011 Feb; 39(2):325-36. PubMed ID: 21270424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.
    Chira EC; McMillen TS; Wang S; Haw A; O'Brien KD; Wight TN; Chait A
    Atherosclerosis; 2007 Nov; 195(1):100-9. PubMed ID: 17214992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PPAR Agonists: II. Fenofibrate and Tesaglitazar Alter Behaviors Related to Voluntary Alcohol Consumption.
    Blednov YA; Black M; Benavidez JM; Stamatakis EE; Harris RA
    Alcohol Clin Exp Res; 2016 Mar; 40(3):563-71. PubMed ID: 26857541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPAR agonists regulate brain gene expression: relationship to their effects on ethanol consumption.
    Ferguson LB; Most D; Blednov YA; Harris RA
    Neuropharmacology; 2014 Nov; 86():397-407. PubMed ID: 25036611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S; Retterstøl K; Ose L; Ohman KP; Lindberg MB; Svensson M
    Metabolism; 2007 Sep; 56(9):1285-92. PubMed ID: 17697874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing design parameters of a peptide targeted liposomal nanoparticle in an in vivo multiple myeloma disease model after initial evaluation in vitro.
    Stefanick JF; Omstead DT; Ashley JD; Deak PE; Mustafaoglu N; Kiziltepe T; Bilgicer B
    J Control Release; 2019 Oct; 311-312():190-200. PubMed ID: 31473250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tesaglitazar: a promising approach in type 2 diabetes.
    Cox SL
    Drugs Today (Barc); 2006 Mar; 42(3):139-46. PubMed ID: 16628256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficiency in Nrf2 transcription factor decreases adipose tissue mass and hepatic lipid accumulation in leptin-deficient mice.
    Xu J; Donepudi AC; More VR; Kulkarni SR; Li L; Guo L; Yan B; Chatterjee T; Weintraub N; Slitt AL
    Obesity (Silver Spring); 2015 Feb; 23(2):335-44. PubMed ID: 25451536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of synthetic peptide-modified liposomes with LDL receptor targeting capacity and improved anticancer activity.
    Liu M; Li W; Larregieu CA; Cheng M; Yan B; Chu T; Li H; Mao SJ
    Mol Pharm; 2014 Jul; 11(7):2305-12. PubMed ID: 24830852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PPAR Agonists: I. Role of Receptor Subunits in Alcohol Consumption in Male and Female Mice.
    Blednov YA; Black M; Benavidez JM; Stamatakis EE; Harris RA
    Alcohol Clin Exp Res; 2016 Mar; 40(3):553-62. PubMed ID: 26857685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.